ReviewJournal of cancer research and clinical oncology2009
Clinical implications of molecular genetic aberrations in acute myeloid leukemia.
Review in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Article
- Identification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis.Disease markers · 2022Article
- Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.Experimental hematology · 2016Review
- Prognostic significance of theMolecular and clinical oncology · 2015Article
- The Role of miRNA in Haematological Malignancy.Bone marrow research · 2013Review
- Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.Annals of laboratory medicine · 2012Article
- Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.Expert opinion on emerging drugs · 2011Review
- Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Cancer · 2011Article
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- CREB and leukemogenesis.Critical reviews in oncogenesis · 2011Review
- Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.American journal of clinical pathology · 2011Article
- Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of different cytogenetic changes has been extensively evaluated in patients with acute myeloid leukemia (AML), and cytogenetic analysis of AML blasts is essential to form prognostic subgroups in order to stratify for the extent of therapy. Nevertheless, 40-45% of AML patients lack such cytogenetic markers, i.e., cytogenetically normal AML (CN-AML). In the past decade, different molecular aberrations were identified in AML and especially CN-AML can now be discriminated into certain prognostic subgroups. This review considers the latest advances to define the prognostic impact of molecular aberrations in AML and gives insights how such molecular markers can be applied for analysis of minimal residual disease. Furthermore, therapeutic implications as well as the potential role of new methodological techniques in analyzing expression patterns of AML blasts are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.